Reaction
Ovarian Cancer Metastatic reporting signals
As of the last recalculation, Ovarian Cancer Metastatic appears in 830 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE (PRR 120.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Conjugated Estrogens And Medroxyprogesterone Acetate | 100 | 120.7 | 121.2 |
| Conjugated Estrogens | 164 | 87.7 | 87.9 |
| Estrogens, Conjugated | 164 | 86.1 | 86.3 |
| Niraparib | 65 | 79.6 | 79.8 |
| Olaparib | 33 | 41.2 | 41.2 |
| Medroxyprogesterone Acetate | 71 | 39.0 | 39.0 |
| Rucaparib | 13 | 37.5 | 37.5 |
| Bevacizumab | 102 | 23.4 | 23.4 |
| Gemcitabine | 34 | 22.5 | 22.5 |
| Paclitaxel (Aibumin-Bound) | 67 | 22.1 | 22.2 |
| Carboplatin | 96 | 21.3 | 21.3 |
| Letrozole Tablets | 35 | 19.0 | 19.0 |
| Paclitaxel | 69 | 19.0 | 19.0 |
| Gemcitabine Hydrochloride | 36 | 17.7 | 17.8 |
| Trametinib | 16 | 16.9 | 16.9 |
| Letrozole | 37 | 15.7 | 15.7 |
| Doxorubicin Hydrochloride | 19 | 14.9 | 14.9 |